Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8)
Publication
, Journal Article
Feigin, A; Evans, EE; Fisher, TL; Leonard, JE; Smith, ES; Reader, A; Mishra, V; Manber, R; Walters, KA; Kowarski, L; Oakes, D; Siemers, E ...
Published in: Nature Medicine
January 1, 2022
In the version of this article initially published, in the first and final paragraphs of the Results section, the dosing schedule for pepinemab administration was described in error as “four times per week” instead of “every four weeks,” while in the Fig. 4b color key, the bottom, dark green key now reading “Much improved” appeared originally as “Minimally improved.” The errors have been corrected in the HTML and PDF versions of the article.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nature Medicine
DOI
EISSN
1546-170X
ISSN
1078-8956
Publication Date
January 1, 2022
Related Subject Headings
- Immunology
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., … Anderson, K. (2022). Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8). Nature Medicine. https://doi.org/10.1038/s41591-022-02070-0
Feigin, A., E. E. Evans, T. L. Fisher, J. E. Leonard, E. S. Smith, A. Reader, V. Mishra, et al. “Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8).” Nature Medicine, January 1, 2022. https://doi.org/10.1038/s41591-022-02070-0.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, et al. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8). Nature Medicine. 2022 Jan 1;
Feigin, A., et al. “Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8).” Nature Medicine, Jan. 2022. Scopus, doi:10.1038/s41591-022-02070-0.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M, Kayson E, Goldstein J, Barbano R, Marder K, Dayalu P, Rosas HD, Kostyk S, Kamholz J, Racette B, Bang J, Claassen D, McDonell K, Factor S, Walker F, Goas C, Wojcieszek J, Raymond LA, Corey-Bloom J, Sung V, Dean M, Geshwind M, Nelson A, Frank S, LaFaver K, Duker A, Elmer L, Samii A, Lin YH, Chouinard S, Seeberger L, Scott B, Boyd J, McFarland N, Stimming EF, Suchowersky O, Testa C, Anderson K. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8). Nature Medicine. 2022 Jan 1;
Published In
Nature Medicine
DOI
EISSN
1546-170X
ISSN
1078-8956
Publication Date
January 1, 2022
Related Subject Headings
- Immunology
- 11 Medical and Health Sciences